Collegium Pharmaceutical, Inc.
NASDAQ:COLL
38.78 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 566.767 | 463.933 | 276.868 | 310.016 | 296.701 | 280.413 | 28.476 | 1.711 | 0 | 0 | 0 |
| Cost of Revenue
| 240.598 | 254.445 | 126.251 | 130.18 | 193.66 | 165.677 | 2.595 | 0.213 | 0.171 | 0 | 0 |
| Gross Profit
| 326.169 | 209.488 | 150.617 | 179.836 | 103.041 | 114.736 | 25.881 | 1.498 | -0.171 | 0 | 0 |
| Gross Profit Ratio
| 0.575 | 0.452 | 0.544 | 0.58 | 0.347 | 0.409 | 0.909 | 0.876 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 0 | 3.983 | 9.451 | 9.772 | 10.34 | 8.661 | 8.572 | 14.948 | 7.975 | 14.959 | 14.157 |
| General & Administrative Expenses
| 151.802 | 160.443 | 114.774 | 108.464 | 0 | 0 | 0 | 0 | 18.932 | 2.706 | 1.885 |
| Selling & Marketing Expenses
| 7.406 | 11.743 | 4.186 | 5.368 | 116.449 | 126.76 | 92.756 | 80.632 | 0 | 0 | 0 |
| SG&A
| 159.208 | 172.186 | 118.96 | 113.832 | 116.449 | 126.76 | 92.756 | 80.632 | 18.932 | 2.706 | 1.885 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.094 | -0.348 | 0 | 0 |
| Operating Expenses
| 159.208 | 176.169 | 128.411 | 123.604 | 126.789 | 135.421 | 101.328 | 95.58 | 26.907 | 17.665 | 16.042 |
| Operating Income
| 166.961 | -104.573 | -46.699 | -5.086 | -23.748 | -20.685 | -75.447 | -94.082 | -26.907 | -17.665 | -16.042 |
| Operating Income Ratio
| 0.295 | -0.225 | -0.169 | -0.016 | -0.08 | -0.074 | -2.649 | -54.987 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -23.504 | 75.726 | 43.325 | 32.668 | 1.026 | -18.443 | 0.582 | -0.094 | -0.348 | -0.252 | -0.079 |
| Income Before Tax
| 75.733 | -28.847 | -3.374 | 27.582 | -22.722 | -39.128 | -74.865 | -94.176 | -27.255 | -17.917 | -16.197 |
| Income Before Tax Ratio
| 0.134 | -0.062 | -0.012 | 0.089 | -0.077 | -0.14 | -2.629 | -55.041 | 0 | 0 | 0 |
| Income Tax Expense
| 27.578 | -3.845 | -74.891 | 0.83 | -14.574 | -110.908 | -1.164 | 0.094 | -0.091 | 0.252 | 0.079 |
| Net Income
| 48.155 | -25.002 | 71.517 | 26.752 | -8.148 | -39.128 | -74.865 | -94.176 | -27.255 | -17.917 | -16.197 |
| Net Income Ratio
| 0.085 | -0.054 | 0.258 | 0.086 | -0.027 | -0.14 | -2.629 | -55.041 | 0 | 0 | 0 |
| EPS
| 1.43 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.4 | -2.17 |
| EPS Diluted
| 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.4 | -2.17 |
| EBITDA
| 331.832 | 34.366 | 22.218 | 56.464 | -21.813 | -18.998 | -74.853 | -94.082 | -26.907 | -17.478 | -15.873 |
| EBITDA Ratio
| 0.585 | 0.074 | 0.08 | 0.182 | -0.074 | -0.068 | -2.629 | -54.987 | 0 | 0 | 0 |